References
- Lls.org [Internet]. New York: Leukemia and Lymphoma Society, 2020; [cited 2020 Oct 22]. Available from: https://www.lls.org/blog/recent-drug-approvals-for-blood-cancer-mark-significant-progress-for-patients
- Al Hadidi S, Mims M, Miller-Chism CN, et al. Participation of African American persons in clinical trials supporting U.S. Food and Drug Administration approval of cancer drugs. Ann Intern Med. 2020;173(4):320–322.
- Walter RB, Appelbaum FR, Tallman MS, et al. Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm. Blood. 2010;116(14):2420–2428.
- Walter RB, Estey EH. The power of comparative studies. Leuk Res. 2009;33(5):610–612.
- Barnes CN, Rai SN. Modeling heterogeneity in phase II clinical trials. Am J Biostat. 2010;6(1):9–16.
- Rowe JM, Yao X, Cassileth PA, et al. The pitfalls of early publication of data in acute myeloid leukemia: a report from the Eastern Cooperative Oncology Group (ECOG) [abstract]. Blood. 2008;112(11):1952–1952.
- Joseph G, Dohan D. Diversity of participants in clinical trials in an academic medical center: the role of the ‘Good Study Patient?’ Cancer. 2009;115(3):608–615.
- Kim C, Prasad V. Cancer drugs approved on the basis of a surrogate end point and subsequent overall survival: an analysis of 5 years of US Food and Drug Administration approvals. JAMA Intern Med. 2015;175(12):1992–1994.
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA A Cancer J Clin. 2020;70(1):7–30.